530 related articles for article (PubMed ID: 17216007)
21. Cisplatin ototoxicity in the Sprague Dawley rat evaluated by distortion product otoacoustic emissions.
Hatzopoulos S; Di Stefano M; Campbell KC; Falgione D; Ricci D; Rosignoli M; Finesso M; Albertin A; Previati M; Capitani S; Martini A
Audiology; 2001; 40(5):253-64. PubMed ID: 11688544
[TBL] [Abstract][Full Text] [Related]
22. Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma.
Kushner BH; Budnick A; Kramer K; Modak S; Cheung NK
Cancer; 2006 Jul; 107(2):417-22. PubMed ID: 16779793
[TBL] [Abstract][Full Text] [Related]
23. Risk factors of ototoxicity after cisplatin-based chemo-irradiation in patients with locally advanced head-and-neck cancer: a multivariate analysis.
Zuur CL; Simis YJ; Lansdaal PE; Hart AA; Rasch CR; Schornagel JH; Dreschler WA; Balm AJ
Int J Radiat Oncol Biol Phys; 2007 Aug; 68(5):1320-5. PubMed ID: 17418969
[TBL] [Abstract][Full Text] [Related]
24. [Electrophysiological evaluation of the hearing function following cisplatin administration].
Bogomol'skiĭ MR; D'iakonova IN; Rakhmanova IV; Sapozhnikov IaM; Stakhovskaia OR; Tikhomirov AM
Vestn Otorinolaringol; 2010; (3):24-6. PubMed ID: 20559247
[TBL] [Abstract][Full Text] [Related]
25. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy.
Weissenstein A; Deuster D; Knief A; Zehnhoff-Dinnesen AA; Schmidt CM
Int J Pediatr Otorhinolaryngol; 2012 Jan; 76(1):131-6. PubMed ID: 22104469
[TBL] [Abstract][Full Text] [Related]
26. Ototoxicity in children treated for osteosarcoma.
Lewis MJ; DuBois SG; Fligor B; Li X; Goorin A; Grier HE
Pediatr Blood Cancer; 2009 Mar; 52(3):387-91. PubMed ID: 19061216
[TBL] [Abstract][Full Text] [Related]
27. The protective effect of intratympanic dexamethasone on cisplatin-induced ototoxicity in guinea pigs.
Daldal A; Odabasi O; Serbetcioglu B
Otolaryngol Head Neck Surg; 2007 Nov; 137(5):747-52. PubMed ID: 17967639
[TBL] [Abstract][Full Text] [Related]
28. [Clinical study on the ototoxicity of cisplatin with distortion products].
Orts Alborch M; García Callejo J; Morant Ventura A; Ferrer Baixauli F; Esparcia Navarro M; Marco Algarra J
Acta Otorrinolaringol Esp; 2000; 51(6):469-77. PubMed ID: 11142781
[TBL] [Abstract][Full Text] [Related]
29. Ototoxicity in children with malignant brain tumors treated with the "8 in 1" chemotherapy protocol.
Ilveskoski I; Saarinen UM; Wiklund T; Perkkiö M; Salmi TT; Lanning M; Mäkipernaa A; Pihko H
Med Pediatr Oncol; 1996 Jul; 27(1):26-31. PubMed ID: 8614387
[TBL] [Abstract][Full Text] [Related]
30. Otoacoustic detection of risk of early hearing loss in ears with normal audiograms: a 3-year follow-up study.
Job A; Raynal M; Kossowski M; Studler M; Ghernaouti C; Baffioni-Venturi A; Roux A; Darolles C; Guelorget A
Hear Res; 2009 May; 251(1-2):10-6. PubMed ID: 19249340
[TBL] [Abstract][Full Text] [Related]
31. Effect of aspirin on phase gradient of 2F1-F2 distortion product otoacoustic emissions.
Parazzini M; Hall AJ; Lutman ME; Kapadia S
Hear Res; 2005 Jul; 205(1-2):44-52. PubMed ID: 15953514
[TBL] [Abstract][Full Text] [Related]
32. [Effects of Cisplatin on Auditory Function in Children with cancer. Otoacoustic Emission Evaluation].
Toral-Martiñón R; Poblano A; Collado-Corona MA; González R
Gac Med Mex; 2003; 139(6):529-34. PubMed ID: 14723047
[TBL] [Abstract][Full Text] [Related]
33. Test-retest repeatability of distortion product otoacoustic emissions.
Wagner W; Heppelmann G; Vonthein R; Zenner HP
Ear Hear; 2008 Jun; 29(3):378-91. PubMed ID: 18382378
[TBL] [Abstract][Full Text] [Related]
34. The use of high-frequency audiometry increases the diagnosis of asymptomatic hearing loss in pediatric patients treated with cisplatin-based chemotherapy.
Abujamra AL; Escosteguy JR; Dall'Igna C; Manica D; Cigana LF; Coradini P; Brunetto A; Gregianin LJ
Pediatr Blood Cancer; 2013 Mar; 60(3):474-8. PubMed ID: 22744939
[TBL] [Abstract][Full Text] [Related]
35. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer.
Bokemeyer C; Berger CC; Hartmann JT; Kollmannsberger C; Schmoll HJ; Kuczyk MA; Kanz L
Br J Cancer; 1998 Apr; 77(8):1355-62. PubMed ID: 9579846
[TBL] [Abstract][Full Text] [Related]
36. Cisplatin administration to gynecologic cancer patients. Long-term effects on hearing.
Laurell G; Beskow C; Frankendal B; Borg E
Cancer; 1996 Oct; 78(8):1798-804. PubMed ID: 8859195
[TBL] [Abstract][Full Text] [Related]
37. End points for cisplatin ototoxicity.
Qureshy K; Blakley B; Alsaleh S; Quddusi T; Berard S
J Otolaryngol Head Neck Surg; 2011 Feb; 40 Suppl 1():S45-8. PubMed ID: 21453661
[TBL] [Abstract][Full Text] [Related]
38. Changes to spontaneous otoacoustic emissions (SOAEs) due to cisplatin administration.
Kuroda T; Chida E; Kashiwamura M; Matsumura M; Fukuda S
Int J Audiol; 2008 Nov; 47(11):695-701. PubMed ID: 19031228
[TBL] [Abstract][Full Text] [Related]
39. High frequency distortion product otoacoustic emissions in children with and without middle ear dysfunction.
Kei J; Brazel B; Crebbin K; Richards A; Willeston N
Int J Pediatr Otorhinolaryngol; 2007 Jan; 71(1):125-33. PubMed ID: 17126413
[TBL] [Abstract][Full Text] [Related]
40. Distortion-product otoacoustic emission: early detection in deferoxamine induced ototoxicity.
Delehaye E; Capobianco S; Bertetto IB; Meloni F
Auris Nasus Larynx; 2008 Jun; 35(2):198-202. PubMed ID: 17869044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
